Pantarhei’s objective is to develop patent protected treatments up to proven efficacy and safety (phase II) in the human. After successful proof-of-concept, the new product is licensed-out to a licensee or (pharmaceutical) company for final clinical development (phase III), regulatory approval and commercialisation.
For detailed information, please contact:
Olav Andriesse, LL.M MBA or
Yvette Zimmerman, PhD
phone: + 31 (0)30 69 85 020